Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

doi:10.1002/jps.2600800905

Journal of Pharmaceutical Sciences

Volume 80, Issue 9, September 1991, Pages 830-834

https://doi.org/10.1002/jps.2600800905 Get rights and content

Abstract

The apparent octanol–water partition coefficients (P_o/w) and aqueous solubilities for four 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors [pravastatin, lovastatin (mevinolin), mevastatin (compactin), and simvastatin (synvinolin)] were compared. Pravastatin is highly hydrophilic compared with lovastatin, mevastatin, or simvastatin. Pravastatin is clinically used as the active hydroxy acid, while the other three compounds are administered as prodrug lactones which, over a period of time, convert in vivo to their respective active hydroxy acid forms. The order of the P_o/w values of the hydroxy acid forms was pravastatin << mevastatin < lovastatin < simvastatin at each pH evaluated, with approximate ratios of 1:25:75:200, respectively. The relative order and the ratios of partition coefficients for the lactone forms were similar to those for the hydroxy acid forms. In addition, lovastatin, mevastatin, and simvastatin are virtually insoluble in water, with solubility values ranging from 0.0013 to 0.0015 mg/mL at 23 °C. In comparison, pravastatin is hydrophilic, as demonstrated by the > 100-fold greater solubility of its lactone form (0.18 mg/mL). The greater hydrophilicity of pravastatin may explain its reported lower permeation into nonhepatic cells and the selectivity with respect to inhibition of cholesterol synthesis.

References (0)

Cited by (199)

Co-milling of β-cyclodextrin with simvastatin: Solid state studies and dissolution profile
2023, Journal of Drug Delivery Science and Technology
Simvastatin is a cholesterol-regulating drug of widespread use in the prevention of cardiovascular diseases associated with dyslipidaemia. Herein we report on the preparation of co-amorphous adducts of simvastatin with the solubilising agent β-cyclodextrin by means of a solvent-free mechanochemical procedure and on the evaluation of their dissolution profiles. Production of co-milled adducts was carried out using a laboratory scale planetary ball mill. The resulting powders were characterised by X-ray powder diffraction, Fourier-transform infrared spectroscopy, differential scanning calorimetry and scanning electron microscopy. Dissolution of simvastatin from the co-milled powders into water was measured by ultra-violet/visible absorption spectroscopy (UV/Vis). Results show that co-amorphisation was obtained after 280 min of milling the two components, with formation of a solid that features a much more favourable dissolution profile and allows simvastatin concentration in aqueous solution to reach a value roughly to nine folds higher than the one obtained by dissolving the pure drug. In conclusion, co-grinding with β-cyclodextrin is a simple and quick method to obtain simvastatin preparations with an improved dissolution profile.
FTIR spectroscopic study of two isostructural statins: Simvastatin and Lovastatin as authentic and in pharmaceuticals
2021, Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy
A very simple, economic analytical method with few sample pretreatment steps has been developed for quantitation of simvastatin in the presence of its isostructure lovastatin without any interference. It was utilized for easy and complete fine characterization of simvastatin FTIR spectrum from that of lovastatin. Simvastatin has been determined efficiently by the developed method either alone or in mixture with lovastatin giving LOQ values of 0.009 and 0.02% w/w, respectively indicating good sensitivity. Acceptable correlation coefficient values of 0.9975 and 0.9886 alone and in mixture with lovastatin, respectively. The developed spectroscopic method has provided simple and sensitive tool in quality control laboratories for efficient quantitation simvastatin in pharmaceutical tablets with good recoveries.
Feasibility of the use of boron-doped diamond electrode coupled to electroanalytical techniques for the individual determination of pravastatin and its association with acetylsalicylic acid
2020, Journal of Electroanalytical Chemistry
Citation Excerpt :
The intersection of these two lines can be explained by the changes in protonation of the acid–base moiety in the molecule. The intersection point at pH 4.32 is attributed to the pKa value for PRAV, close to the one reported in the literature, which is related to the loss of a proton from the carboxyl group [35]. Concerning the peak currents, the higher oxidation peaks were obtained at pH 4.0 and 5.0; however, considering the repeatability of current intensity, pH 4.0 was selected for further experiments.
In this work, we explored the efficiency of the use of the pretreated boron-doped diamond electrode (BDDE) coupled to electroanalytical techniques for the individual determination of pravastatin (PRAV) and its association with acetylsalicylic acid (ASA). The voltammetric behavior of PRAV and ASA was investigated by cyclic voltammetry showing irreversible and diffusion-controlled oxidation processes for both analytes, regardless of the type of BDDE pretreatment. Under the optimized conditions (cathodically pretreated BDDE and phosphate buffer solution, pH 4.0), the analytical response for PRAV was linear over the range from 1.0 to 30 μmol L⁻¹ for individual determination using amperometry, obtaining a limit of detection (LOD) of 0.102 μmol L⁻¹. For simultaneous determination of PRAV and ASA, (using the anodically pretreated BDDE in 0.3 mol L⁻¹ H₂SO₄ solution), the responses were linear over the range of 1.08–16.4 μmol L⁻¹ for PRAV and 3.96–42.75 μmol L⁻¹ for ASA using SWV, obtaining a LOD of 0.204 and 0.078 μmol L⁻¹, respectively. The methods were successfully applied to pharmaceutical formulations, synthetic urine and tap water samples.
Differential effects of simvastatin on membrane organization and dynamics in varying phases
2019, Chemistry and Physics of Lipids
Simvastatin belongs to the statin family of cholesterol lowering drugs which act as competitive inhibitors of HMG-CoA reductase, the rate-determining enzyme in cholesterol biosynthesis pathway. Simvastatin is a semi-synthetic, highly lipophilic statin, and has several side effects. Since HMG-CoA reductase is localized in the endoplasmic reticulum, orally administered simvastatin needs to cross the cellular plasma membrane to be able to act on HMG-CoA reductase. With an overall goal of exploring the interaction of simvastatin with membranes, we examined the effect of simvastatin on the organization and dynamics in membranes of varying phase, in a depth-dependent manner. For this, we employed DPH and TMA-DPH, which represent fluorescent membrane probes localized at two different locations (depths) in the membrane. Analysis of fluorescence anisotropy and lifetime data of these depth-specific probes in membranes of varying phase (gel/fluid/liquid-ordered) showed that the maximum membrane disordering was observed in gel phase, while moderate effects were observed in liquid-ordered phase, with no significant change in membrane order in fluid phase membranes. We conclude that simvastatin induces change in membrane order in a depth-dependent and phase-specific manner. These results provide novel insight in the membrane interaction of simvastatin and could be crucial for understanding its pharmacological effect.
Interaction of the cholesterol reducing agent simvastatin with zwitterionic DPPC and charged DPPG phospholipid membranes
2019, Biochimica et Biophysica Acta - Biomembranes
Citation Excerpt :
Under physiological pH conditions of 7–7·4, the relative lipophilicity of various statins currently in clinical use was: simvastatin ≈ cerivastatin > lovastatin ≈ fluvastatin ≈ atorvastatin ≫ pravastatin, where simvastatin is 100 times more lipophilic than pravastatin and pravastatin is 70- to 300-times more hydrophilic than the other statins [7]. The lipophilicity of statins provides a more uptake in peripheral tissues resulting in higher inhibition of cholesterol synthesis [10,11]. Simvastatin is one of the well clarified statins having high efficacy in reducing LDL cholesterol levels, high tolerability, and high capacity of cardiovascular risk and mortality reduction [12].
Simvastatin is a lipid-lowering drug in the pharmaceutical group statins. Interaction of a drug with lipids may define its role in the system and be critical for its pharmacological activity. We examined the interactions of simvastatin with zwitterionic dipalmitoyl phosphatidylcholine (DPPC) and anionic dipalmitoyl phosphatidylglycerol (DPPG) multilamellar vesicles (MLVs) as a function of temperature at different simvastatin concentrations using Fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC). The FTIR results indicate that the effect of simvastatin on membrane structure and dynamics depends on the type of membrane lipids. In anionic DPPG MLVs, high simvastatin concentrations (12, 18, 24 mol%) change the position of the CH₂ antisymmetric stretching mode to lower wavenumber values, implying an ordering effect. However, in zwitterionic DPPC MLVs, high concentrations of simvastatin disorder systems both in the gel and liquid crystalline phases. Moreover, in DPPG and DPPC MLVs, simvastatin has opposite dual effects on membrane dynamics. The bandwidth of the CH₂ antisymmetric stretching modes increases in DPPG MLVs, implying an increase in the dynamics, whereas it decreases in DPPC MLVs. Simvastatin caused broadening of the phase transition peaks and formation of shoulders on the phase transition peaks in DSC curves, indicating multi-domain formations in the phospholipid membranes. Because physical features of membranes such as lipid order and fluidity may be changed with the bioactivity of drugs, opposing effects of simvastatin on the order and dynamics of neutral and charged phospholipids may be critical to deduce the action mechanism of the drug and estimate drug-membrane interactions.
Liquid chromatography | Pharmaceutical applications
2019, Encyclopedia of Analytical Science
Liquid chromatography (LC) has been applied in the pharmaceutical industry almost from the inception of the technique. In this article, the overview of recent advancements in LC, like ultra-high-performance liquid chromatography and superficially porous particle technology, which were adopted to analysis of pharmaceuticals can be found. The utilization of liquid chromatography during development and manufacturing stages of small molecule drugs is described. That includes aspects of purification, isolation, identification and stability, among others. The article also considers application of modern LC strategies to analysis of the currently most emerging group of drugs, biopharmaceuticals. Finally, the LC approaches for metabolomics in drug discovery as well as pharmacometabolomics are discussed.

View all citing articles on Scopus

View full text

ArticlesRelative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

Abstract

Articles
Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin